|
|
Retreatment with sofosbuvir plus grazoprevir plus elbasvir plus ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir plus ledipasvir or plus daclatasvir or plus simeprevir regimen (ANRS HC34 REVENGE study)
Victor De Ledinghen
,
Claire Laforest
,
Christophe Hézode
,
Stanislas Pol
,
Alain Renault
et al.
Hepatology, 2017, 64 (6), pp.1130A--1130A
Journal articles
hal-01487921v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort
Sepolene Brichler
,
Richard Layese
,
Valérie Bourcier
,
Carole Cagnot
,
Patrick Marcellin
et al.
Hepatology, 2016, 63 (1 SUPP), pp.898A--899A
Journal articles
hal-01414692v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study
Dominique Roulot
,
Vincent Thibault
,
Claire Laforest
,
Hélène Fontaine
,
Jean-Pierre Bronowicki
et al.
Journal articles
hal-01717743v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study
Xavier Adhoute
,
Guillaume Penaranda
,
Jean L. Raoul
,
Jean F. Blanc
,
Julien Edeline
et al.
Journal articles
hal-01310454v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
How to guide sorafenib for advanced hepatocellular carcinoma? Usefulness of NIACE score
Xavier Adhoute
,
Guillaume Penaranda
,
Jean Luc Raoul
,
Jean Frederic Blanc
,
Julien Edeline
et al.
Journal of Gastroenterology and Hepatology, 2015, 30, pp.340--340
Journal articles
hal-01259235v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Marc Bourlière
,
Jean-Pierre Bronowicki
,
Victor de Ledinghen
,
Christophe Hézode
,
Fabien Zoulim
et al.
Journal articles
hal-01134440v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program
Christophe Hézode
,
Victor De Ledinghen
,
Hélène Fontaine
,
Fabien Zoulim
,
Pascal Lebray
et al.
Journal articles
hal-01380169v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890
Christophe Hézode
,
Hélène Fontaine
,
Céline Dorival
,
Dominique Larrey
,
Fabien Zoulim
et al.
Journal articles
hal-01708037v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy
Farid Kheloufi
,
Eric Bellissant
,
Laurent Cotte
,
Isabelle Poizot-Martin
,
Sylvie Quaranta
et al.
Journal articles
hal-01372823v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|